About Diaxxo AG

Diaxxo develops a compact RT-qPCR testing platform that delivers accurate molecular diagnostics in under 45 minutes, utilizing a unique cartridge system for sample extraction and amplification. This technology addresses the need for affordable and rapid point-of-care testing, significantly reducing costs and turnaround times compared to traditional PCR diagnostics.

```xml <problem> Traditional PCR diagnostics often require specialized laboratory infrastructure, leading to high costs and long turnaround times, especially in point-of-care settings and resource-limited environments. The need for trained personnel and complex workflows further limits accessibility and widespread adoption of rapid molecular testing. </problem> <solution> Diaxxo has developed a compact, point-of-care RT-qPCR platform that delivers rapid and accurate molecular diagnostics in under 45 minutes. The system utilizes a unique two-component cartridge system consisting of an extraction cartridge for sample preparation and a pre-loaded reagent cartridge (diaxxoPod) for amplification and detection. The diaxxoCare device combines sample extraction and PCR amplification in a single, user-friendly platform, reducing the need for specialized training and infrastructure. This integrated approach enables faster, easier, and more cost-effective PCR testing at the point of care. </solution> <features> - All-in-one system integrating sample extraction and RT-qPCR amplification - Proprietary extraction cartridge for rapid DNA/RNA purification from various sample types (swabs, saliva, etc.) - Pre-loaded reagent cartridges (diaxxoPods) for specific target detection - Fast thermocycling technology enabling results in under 45 minutes - Point-of-care design suitable for small and medium-sized laboratories - Cost-effective testing with low cost-per-test - User-friendly interface with direct result display </features> <target_audience> The primary target audience includes small to medium-sized laboratories, point-of-care facilities, and healthcare providers seeking rapid and affordable molecular diagnostic solutions. </target_audience> <revenue_model> The company generates revenue through the sale of diaxxoCare devices and consumable cartridges (extraction cartridges and diaxxoPods). The cost per test is less than 10 EUR. </revenue_model> ```

What does Diaxxo AG do?

Where is Diaxxo AG located?

Diaxxo AG is based in Aurich.

When was Diaxxo AG founded?

Diaxxo AG was founded in 2020.

Location

Aurich

Founded

2020

Employees

11 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Diaxxo AG

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

diaxxo.com 1K+

Founded 2020 – Aurich

Funding

No funding information available.

Team (10+)

No team information available.

Company Description

Problem

Traditional PCR diagnostics often require specialized laboratory infrastructure, leading to high costs and long turnaround times, especially in point-of-care settings and resource-limited environments. The need for trained personnel and complex workflows further limits accessibility and widespread adoption of rapid molecular testing.

Solution

Diaxxo has developed a compact, point-of-care RT-qPCR platform that delivers rapid and accurate molecular diagnostics in under 45 minutes. The system utilizes a unique two-component cartridge system consisting of an extraction cartridge for sample preparation and a pre-loaded reagent cartridge (diaxxoPod) for amplification and detection. The diaxxoCare device combines sample extraction and PCR amplification in a single, user-friendly platform, reducing the need for specialized training and infrastructure. This integrated approach enables faster, easier, and more cost-effective PCR testing at the point of care.

Features

All-in-one system integrating sample extraction and RT-qPCR amplification

Proprietary extraction cartridge for rapid DNA/RNA purification from various sample types (swabs, saliva, etc.)

Pre-loaded reagent cartridges (diaxxoPods) for specific target detection

Fast thermocycling technology enabling results in under 45 minutes

Point-of-care design suitable for small and medium-sized laboratories

Cost-effective testing with low cost-per-test

User-friendly interface with direct result display

Target Audience

The primary target audience includes small to medium-sized laboratories, point-of-care facilities, and healthcare providers seeking rapid and affordable molecular diagnostic solutions.

Revenue Model

The company generates revenue through the sale of diaxxoCare devices and consumable cartridges (extraction cartridges and diaxxoPods). The cost per test is less than 10 EUR.